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INTRODUCTION:  Giant  insulinomas  are  extremely  rare  pancreatic  neuroendocrine  tumor.
PRESENTATION  OF  CASE:  A 15-year-old  man  presenting  with  acute  onset  of  lightheadedness  was  found
to  have  serum  glucose  of  1.5  mmol/L.  The  blood  collected  from  the hypoglycemic  episode  showed  an
inappropriately  high  insulin  and C-peptide  level.  Abdominal  computerized  tomography  showed  a 12.5 cm
well-deﬁned,  lobulated  hypervascular  mass  at pancreatic  tail,  without  any  evidence  of  metastasis.  En  bloc
resection  with  distal  pancreatectomy,  and splenectomy  was  successfully  performed.  The  pathologicaliant insulinoma
nsulinoma
ancreatic neuroendocrine tumor
ase report
examination  conﬁrmed  insulinoma,  with  benign  characteristics.  Follow-up  after  the  procedure  revealed
neither  hypoglycemic,  nor  hyperglycemia.
CONCLUSION:  We  report  the  youngest  case  of  a giant  insulinoma.  Despite  the  size  of  the  tumor,  the
pathological  report  conﬁrmed  the  benign  characteristics.  However,  long-term  follow-up  is still essential
to  detect  recurrence  in  the future.
© 2016  The  Author(s).  Published  by  Elsevier  Ltd  on behalf  of IJS  Publishing  Group  Ltd.  This  is  an  open
he  CCaccess  article  under  t
. Introduction
Insulinomas are rare neoplasms with a reported incidence of 4
ases per million population-year [1]. The majority of patients are
bove 50 years of age and is slightly more common in women  than
en [2]. Insulinomas are usually very small, with 80% being less
han 2 cm in diameter [3]. Giant insulinomas (>9 cm in diameter)
re even extremely rare. Less than 40 cases were reported since
927 [4–6]. Mean age at the presentation was 54 years, with the
oungest reported case at 29 years. Most giant insulinomas showed
etastatic features at the time of diagnosis. We report an excep-
ional case of a 12.5 cm insulinoma in a 15-year-old patient with
enign characteristics.
.1. Presentation of case
A 15-year-old man  was seen at emergency department with
cute onset of lightheadedness, diaphoresis, and palpitations in
he evening after fasting for 7 h. He had experienced repetitive
pisodes of dizziness for 2 months without any weight change.
is serum glucose level was 1.5 mmol/L. His symptoms resolved
fter dextrose administration. He had no family history of insu-
∗ Corresponding author at: Anandamahidol Hospital, 35, M6,  Muang District, Lop-
uri 15000, Thailand.
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linoma or multiple endocrine neoplasia type 1 (MEN-1). Physical
exams showed a large palpable mass at left upper quadrant of the
abdomen.
The subsequent analysis of the blood collected from the hypo-
glycemic episode showed an inappropriately high insulin level
of 13.34 U/mL (normal <3 U/mL), and a high C-peptide level
of 2.2 ng/mL (normal < 0.6 ng/mL). Abdominal contrast-enhanced
computed tomographic (CT) scan showed a large well-deﬁned,
lobulated hypervascular mass with areas of low attenuation and
calciﬁcations at pancreatic tail, measuring 12 cm in largest diam-
eter. The mass was  adjacent to stomach, spleen, and left kidney.
There were no pancreatic duct dilatation, no liver mass and no
signiﬁcant abdominal lymphadenopathy (Fig. 1). Serum intact
parathyroid hormone (iPTH), calcium, and prolactin level were all
normal.
The patient was  admitted for continuous glucose infusion
and frequent meals intake. The plasma glucose was maintained
between 3.5–5 mmol/L by average glucose infusion at 10 g/hour.
Esophagogastroduodenoscopy (EGD) was  performed to exclude
gastrointestinal tract invasion. Ten days after his admission, the
patient underwent surgical exploration. Careful palpation demon-
strated splenic attachment but not kidney. Therefore, en bloc
resection with distal pancreatectomy, together with splenectomy
was performed. The patient did not receive vaccination 2-week
prior to surgery due to the urgency of the operation. The gross
appearance showed 12.5 × 10.0 × 8.3 cm mass located at the pan-
creatic tail. Cut sections of the mass showed gray tan surface with
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. CT of the abdomen showing the pancreatic mass in (from left to right, respectively) pre-contrast, arterial, and portal phase.
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ocal hemorrhage. The mass was attached with the splenic capsule
ithout splenic invasion (Fig. 2).
Histopathological examination revealed complete ﬁbrous
ncapsulated mass composed of neoplastic cells arranging in cord,
est, insular and trabecular pattern (Fig. 3A–C). Immunological
taining was positive for chromogranin, synaptophysin, insulin.
i67 nuclear staining was positive at about 1–2%. Staining for Congo
ed, glucagon, and somatostatin was negative (Fig. 3D–H). The neo-
lastic cells had uniformed round nuclei with stippled nuclear
hromatin and indistinct nucleoli without angiolymphatic or per-
neural invasion. Mitotic ﬁgures were 3–4/10 high power ﬁeld
HPF). The tumor was conﬁned in pancreas without splenic cap-
ular invasion. All three resected lymph nodes showed no sign of
etastasis.
Postoperative cause was uneventful. The latest follow-up of
he patient (6 months after the procedure) revealed neither hypo-
lycemic, nor hyperglycemia. Post-splenectomy vaccination was
erformed.
. Discussion
Insulinomas are rare pancreatic neuroendocrine tumors (PNET),
hich are mostly small at diagnosis. Giant insulinomas (>9 cm
iameter) are even rarer. A giant insulinoma measuring 12.5 cm
ound in a 15-year-old man  is very atypical. Our patient presented
ith typical Whipple triad. He reported only 2 month durationthology.
of symptoms before the diagnosis. High serum C-peptide and
insulin level, in contrast with low plasma glucose level, conﬁrmed
the endogenous hyperinsulinemia. From these laboratory ﬁndings,
the differential diagnosis was insulinoma, malignant insulinoma,
ectopic insulin secreting tumor, and noninsulinoma pancreatoge-
nous hypoglycemia syndrome (NIPHS). The mass palpable in this
patient might represent intraabdominal insulin-secreting tumor
such as insulinoma, and malignant insulinoma. In extremely rare
cases, some malignancies were also previously reported to secrete
insulin, such as gastrointestinal stromal tumor [7]. NIPHS could
cause hypoglycemia from endogenous hyperinsulinism, but pal-
pable mass in this patient could not explain this syndrome. Tumor
was easily localized at pancreas by abdominal CT due to the large
size. The CT result helped rule out NIPHS and made ectopic insulin
secreting tumor unlikely. The diagnosis of insulinoma was  con-
ﬁrmed by the positive staining for insulin while being negative for
other hormones.
Diagnosing an insulinoma in youths as in our patient should
raise the concern for genetic diseases. A case of giant insulinoma
was previously reported to be associated with MEN-1 [8]. Yet, nor-
mal  serum intact PTH, calcium and prolactin level helped exclude
MEN-1 syndrome in this patient.Surgical excision is the treatment of choice for insulinomas.
In the small ones, simple enucleation or a distal pancreatectomy
could be done. More aggressive surgical procedure is needed
for larger tumors, requiring Whipple or total pancreatectomy
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Fig. 3. Histopathology of the pancreatic mass (H&E): Low magniﬁcation shows neoplastic cells arranging in cord, nest, insular and trabecular pattern (A). The neoplastic cells
are  intervened by capillary networks (B). The neoplastic cells had uniformed round nuclei with stippled nuclear chromatin and indistinct nucleoli (C). Immunohistochemical
s ntibo
o
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p
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c
etudy  demonstrates the neoplastic cells with positive immunoreactivity to insulin a
f  the tumor cells with immunoreactivity for Glucagon (G) and Somatostatin (H).
echniques. Tumor invasion should also be considered. Stom-
ch, spleen, and left kidney adjacency was shown by CT in this
atient. Preoperative EGD helped exclude stomach invasion, thus
artial gastrectomy might be unnecessary in this patient. How-
ver, whether to perform partial nephrectomy or splenectomy
ould not be determined preoperatively. Some noninvasive pro-
edures such as ﬂuorine-18-l-dihydroxyphenylalanine positron
mission tomography (18F-DOPA PET), could help localize and ver-dy (D), the neuroendocrine marker synaptophysin (E), chromogranin (F), and none
ify adjacent organ invasion [9]. Nevertheless, these studies are
limited in some patients [10], are not available in our institute,
and have very limited availability in Thailand. Exploration was
therefore performed to determine the organ invasion. After peri-
operative ﬁndings, en bloc resection with distal pancreatectomy
was considered to ensure tumor-free margins. Splenectomy was
also performed because of the splenic attachment.
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From pathological report, the tumor conﬁnement in the pan-
reas without local invasion, less than 2% Ki67 positive staining,
niformed round nuclei, regular distribution of nuclear chromatin,
ndistinct nucleoli, present of chromogranin and synaptophysin,
nd the absent of angiolymphatic or perineural invasion displayed
he favourable benign ﬁndings; however, more than two  mitoses
er 10 HPF slightly increased the risk of malignancy [11]. Due to
he large size of tumor, more than 60% of patients with giant insuli-
omas present metastatic features or evidence of local invasion at
he time of the diagnosis [4]. This is much higher than the 4–13.6%
eported in most insulinoma series [1,3]. Therefore, our patient is
ow currently scheduled for the life-long follow-up.
Our patient is interesting because of the extreme age at presen-
ation, which is the youngest reported case of a giant insulinoma.
espite the huge size of the tumor and the splenic attachment, the
athological report conﬁrmed the benign characteristics.
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